#BEGIN_DRUGCARD DB00863

# AHFS_Codes:
56:28.12

# ATC_Codes:
A02BA02
A02BA07

# Absorption:
Approximately 50% bioavailability orally.

# Biotransformation:
Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.

# Brand_Mixtures:
Tritec (ranitidine bismuth citrate salt)

# Brand_Names:
Alquen
Alter-H2
Alvidina
Apo-Ranitidin
Artomil
Azuranit
Coralen
Digestosan
Ergan
Esofex
Fendibina
Gastrial
Gastridina
Gastrolav
Gastrosedol
Kuracid
Label
Lake
Logat
Melfax
Microtid
Mideran
Neugal
Noctone
Noktome
Normon
Novo-Radinine
Nu-Ranit
Pep-Rani
Ptinolin
Quadrin
Quantor
RAN
Radin
Ran H2
Ran Lich
Rani 2
Rani AbZ
Rani-BASF
Rani-Puren
Rani-Q
Rani-Sanorania
Rani-nerton
Raniben
Raniberl
Raniberta
Ranibloc
Ranic
Ranicux
Ranidil
Ranidin
Ranidine
Ranidura
Ranifur
Ranigasan
Ranigast
Ranigen
Ranilonga
Ranimerck
Raniogas
Raniplex
Ranisan
Ranitab
Ranitic
Ranitidin
Ranitidin 1A Pharma
Ranitidin AL
Ranitidin AWD
Ranitidin Arcana
Ranitidin Atid
Ranitidin Basics
Ranitidin Duncan
Ranitidin Dyna
Ranitidin Helvepharm
Ranitidin Heumann
Ranitidin Hexal
Ranitidin Merck
Ranitidin Millet
Ranitidin NM
Ranitidin Normon
Ranitidin PB
Ranitidin Stada
Ranitidin von ct
Ranitidin-Cophar
Ranitidin-Isis
Ranitidin-ratiopharm
Ranitidina Tamarang
Ranitidina predilu Grif
Ranitiget
Ranitin
Ranitine
Ranobel
Rantacid
Ranuber
Raticina
Regalil
Renatac
Rozon
Rubiulcer
Santanol
Serviradine
Sostril
Tanidina
Taural
Terposen
Toriol
Trigger
Ulcecur
Ulcex
Ulcirex
Ulcodin
Ulcolind Rani
Ulsaven
Ultidine
Viserul
Zandid
Zantac
Zantac 150
Zantac 75
Zantac In Plastic Container
Zantarac
Zantic

# CAS_Registry_Number:
66357-35-5

# ChEBI_ID:
8776

# Chemical_Formula:
C13H22N4O3S

# Chemical_IUPAC_Name:
dimethyl[(5-{[(2-{[(E)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
740748

# Description:
A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [PubChem]

# Dosage_Forms:
Solution	Intravenous
Solution	Oral
Tablet	Oral

# Drug_Category:
Anti-Ulcer Agents
Histamine H2 Antagonists

# Drug_Interactions:
Acenocoumarol	Ranitidine may increase the anticoagulant effect of acenocoumarol. (Conflicting evidence)
Anisindione	Ranitidine may increase the anticoagulant effect of anisindione. (Conflicting evidence)
Atazanavir	Ranitidine may decrease the levels/effects of atazanavir.
Cefditoren	H2-Antagonists such as ranitidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.
Dasatinib	Ranitidine may decrease the serum level of dasatinib.
Dicumarol	Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)
Itraconazole	The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole.
Ketoconazole	The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole.
Procainamide	The histamine H2-receptor antagonist, ranitidine, may increase the effect of procainamide.
Rilpivirine	Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy.
Tolazoline	Anticipated loss of efficacy of tolazoline
Vismodegib	Vismodegib serum concentrations may be decreased by histamine 2 receptor antagonists such as ranitidine.
Warfarin	Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-6.31

# Experimental_LogP_Hydrophobicity:
0.27

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
24.7 mg/mL

# Food_Interactions:
Avoid alcohol.
Avoid excessive quantities of coffee or tea (Caffeine).
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Ranitidine

# HET_ID:
Not Available

# Half_Life:
2.8-3.1 hours

# InChI_Identifier:
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+

# InChI_Key:
InChIKey=VMXUWOKSQNHOCA-UKTHLTGXSA-N

# Indication:
Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00422

# LIMS_Drug_ID:
863

# Mechanism_Of_Action:
The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

# Melting_Point:
69-70 Â°C

# Molecular_Weight_Avg:
314.404

# Molecular_Weight_Mono:
314.14126128

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Ranitidine Pathway	SMP00230

# PharmGKB_ID:
PA451224

# Pharmacology:
Ranitidine is a histamine H2-receptor antagonist similar to cimetidine and famotidine. An H2-receptor antagonist, often shortened to H2 antagonist, is a drug used to block the action of histamine on parietal cells in the stomach, decreasing acid production by these cells. These drugs are used in the treatment of dyspepsia, however their use has waned since the advent of the more effective proton pump inhibitors. Like the H1-antihistamines, the H2 antagonists are inverse agonists rather than true receptor antagonists.

# Predicted_LogP_Hydrophobicity:
0.79

# Predicted_LogS:
-3.6

# Predicted_Water_Solubility:
7.95e-02 g/l

# Primary_Accession_No:
DB00863

# Protein_Binding:
15%

# PubChem_Compound_ID:
3001055

# PubChem_Substance_ID:
46505543

# RxList_Link:
http://www.rxlist.com/cgi/generic2/ranitbc.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00254

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Ranitidine HCL
Ranitidine hydrochloride
Rantidine HCL

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub>=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.

# Update_Date:
2013-02-08 16:19:42 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ranitidine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_2_ID:
4119

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_3_ID:
4200

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_4_ID:
4512

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_5_ID:
6016

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
7554999	Pattichis K, Louca LL: Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Drug Metabol Drug Interact. 1995;12(1):1-36.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HRH2

# Drug_Target_1_GenBank_ID_Gene:
M64799

# Drug_Target_1_GenBank_ID_Protein:
184088

# Drug_Target_1_GeneCard_ID:
HRH2

# Drug_Target_1_Gene_Name:
HRH2

# Drug_Target_1_Gene_Sequence:
>1080 bp
ATGGCACCCAATGGCACAGCCTCTTCCTTTTGCCTGGACTCTACCGCATGCAAGATCACC
ATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGT
CTGGCCGTGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTG
GCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGCCATCTACCAGCTG
TCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATG
CTCTGCACAGCCTCCATTCTTAACCTCTTCATGATCAGCCTCGACCGGTACTGCGCTGTC
ATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTC
TTAATTTGGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGC
AGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGTCCAGGTCAATGAA
GTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATC
ACCTACTACCGCATCTTCAAGGTCGCCCGGGATCAGGCCAAGAGGATCAATCACATTAGC
TCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATG
GGGGCCTTCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGA
GGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCTGGGCTATGCCAAC
TCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAA
CAGCTCTTCTGCTGCAGGCTGGCCAACCGCAACTCCCACAAAACTTCTCTGAGGTCCAAC
GCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTG
AAGCTCCAGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10371214	Murakami H, Sun-Wada GH, Matsumoto M, Nishi T, Wada Y, Futai M: Human histamine H2 receptor gene: multiple transcription initiation and tissue-specific expression. FEBS Lett. 1999 May 28;451(3):327-31.
1714721	Gantz I, Munzert G, Tashiro T, Schaffer M, Wang L, DelValle J, Yamada T: Molecular cloning of the human histamine H2 receptor. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1386-92.
7755641	Nishi T, Koike T, Oka T, Maeda M, Futai M: Identification of the promoter region of the human histamine H2-receptor gene. Biochem Biophys Res Commun. 1995 May 16;210(2):616-23.
8817552	Orange PR, Heath PR, Wright SR, Pearson RC: Allelic variations of the human histamine H2 receptor gene. Neuroreport. 1996 May 17;7(7):1293-6.
9374694	Del Valle J, Gantz I: Novel insights into histamine H2 receptor biology. Am J Physiol. 1997 Nov;273(5 Pt 1):G987-96.

# Drug_Target_1_HGNC_ID:
HGNC:5183

# Drug_Target_1_HPRD_ID:
00816

# Drug_Target_1_ID:
124

# Drug_Target_1_Locus:
5q35.2

# Drug_Target_1_Molecular_Weight:
40099

# Drug_Target_1_Name:
Histamine H2 receptor

# Drug_Target_1_Number_of_Residues:
359

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Histamine H2 receptor
MAPNGTASSFCLDSTACKITITVVLAVLILITVAGNVVVCLAVGLNRRLRNLTNCFIVSL
AITDLLLGLLVLPFSAIYQLSCKWSFGKVFCNIYTSLDVMLCTASILNLFMISLDRYCAV
MDPLRYPVLVTPVRVAISLVLIWVISITLSFLSIHLGWNSRNETSKGNHTTSKCKVQVNE
VYGLVDGLVTFYLPLLIMCITYYRIFKVARDQAKRINHISSWKAATIREHKATVTLAAVM
GAFIICWFPYFTAFVYRGLRGDDAINEVLEAIVLWLGYANSALNPILYAALNRDFRTGYQ
QLFCCRLANRNSHKTSLRSNASQLSRTQSREPRQQEEKPLKLQVWSGTEVTAPQGATDR

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway

# Drug_Target_1_SwissProt_ID:
P25021

# Drug_Target_1_SwissProt_Name:
HRH2_HUMAN

# Drug_Target_1_Synonyms:
Gastric receptor I
H2R

# Drug_Target_1_Theoretical_pI:
9.39

# Drug_Target_1_Transmembrane_Regions:
23-44
58-81
93-114
135-159
181-204
235-258
268-289

#END_DRUGCARD DB00863
